IAIP Therapy

About ProThera Biologics

ProThera Biologics, founded in 2001, is developing first-in-class biologic therapies based on Inter-alpha Inhibitor Proteins (IAIP) to treat severe inflammatory conditions with high unmet need. The company's platform leverages a multi-pathway anti-inflammatory mechanism, targeting complex diseases like severe community-acquired pneumonia, stroke, and neonatal hypoxic-ischemic brain injury. As a private, likely pre-revenue entity, ProThera is advancing both therapeutic and diagnostic (biomarker) applications of IAIP, positioning itself in a challenging but high-potential segment of the immunology market.

About ProThera Biologics

ProThera Biologics, founded in 2001, is developing first-in-class biologic therapies based on Inter-alpha Inhibitor Proteins (IAIP) to treat severe inflammatory conditions with high unmet need. The company's platform leverages a multi-pathway anti-inflammatory mechanism, targeting complex diseases like severe community-acquired pneumonia, stroke, and neonatal hypoxic-ischemic brain injury. As a private, likely pre-revenue entity, ProThera is advancing both therapeutic and diagnostic (biomarker) applications of IAIP, positioning itself in a challenging but high-potential segment of the immunology market.

About ProThera Biologics

ProThera Biologics, founded in 2001, is developing first-in-class biologic therapies based on Inter-alpha Inhibitor Proteins (IAIP) to treat severe inflammatory conditions with high unmet need. The company's platform leverages a multi-pathway anti-inflammatory mechanism, targeting complex diseases like severe community-acquired pneumonia, stroke, and neonatal hypoxic-ischemic brain injury. As a private, likely pre-revenue entity, ProThera is advancing both therapeutic and diagnostic (biomarker) applications of IAIP, positioning itself in a challenging but high-potential segment of the immunology market.

Therapeutic Areas

Other Severe Community Acquired Pneumonia Drugs